Aprea Therapeutics (APRE)

• Market cap: $8.27M
• 1 day: 5.97%
• 5 days: -4.05%
• 1 month: -5.96%
• 3 months: -24.47%
• 6 months: -18.86%
• Year to date: -60.22%
• 1 year: -66.82%
• 5 years: -99.7%
• 10 years: -99.65%
• Sector: Healthcare
• Industry: Biotechnology

About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Employees: 8